GSK Bought September and November 2026: The $10.6 Billion Nuvalent Autopsy
GSK Did Not Simply Buy Nuvalent. It Bought Two FDA Decision Dates | Witfire Elite View Witfire Elite Oncology M&A Case Studies Strategy Long Read Pharma Market Case…
Archive
Category: Pharma Market Case Studies
India CRO Boom: Why India’s Next CRO Boom May Be Built on Molecules It Did Not Invent
India CRO Boom: Why Chinese Molecules May Build the Next Outsourcing Wave | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case…
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies…
CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper problem is that CagriSema is being asked to solve a…
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the world is made in India — and the price collapse…
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case Study…
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite…
Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug
Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case…
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market…
FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I
FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read…